STAA Quote, Financials, Valuation and Earnings

OrthoPediatrics has a net margin of -69.92% compared to Staar Surgical's net margin of -30.51%. Staar Surgical's return on equity of -5.02% beat OrthoPediatrics's return on equity of -10.25%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand OrthoPediatrics has an analysts' consensus of $39.00 which suggests that it could grow by 56.25%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.767%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. Staar Surgical's net income of -$34.2M is lower than OrthoPediatrics's net income of -$16.1M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.81x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -69.92% compared to Staar Surgical's net margin of -678.5%. Staar Surgical's return on equity of -5.02% beat Innovative Eyewear's return on equity of -113.55%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand Innovative Eyewear has an analysts' consensus of -- which suggests that it could grow by 279.4%. Given that Innovative Eyewear has higher upside potential than Staar Surgical, analysts believe Innovative Eyewear is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than Innovative Eyewear quarterly revenues of $253.6K. Staar Surgical's net income of -$34.2M is lower than Innovative Eyewear's net income of -$1.7M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.41x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -69.92% compared to Staar Surgical's net margin of -23.57%. Staar Surgical's return on equity of -5.02% beat NexGel's return on equity of -67.5%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand NexGel has an analysts' consensus of -- which suggests that it could grow by 107.61%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than NexGel quarterly revenues of $2.9M. Staar Surgical's net income of -$34.2M is lower than NexGel's net income of -$693K. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.63x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of -69.92% compared to Staar Surgical's net margin of 12.15%. Staar Surgical's return on equity of -5.02% beat Pro-Dex's return on equity of 21.59%.

Staar Surgical has a consensus price target of $18.67, signalling upside risk potential of 5.97%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 10.45%. Given that Pro-Dex has higher upside potential than Staar Surgical, analysts believe Pro-Dex is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.660, which suggesting that the stock is 34.006% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $49M, which are larger than Pro-Dex quarterly revenues of $16.8M. Staar Surgical's net income of -$34.2M is lower than Pro-Dex's net income of $2M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Pro-Dex's PE ratio is 24.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 2.77x versus 2.73x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.